Duloxetine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Duloxetine: From Major Depressive Disorder to Obsessive-Compulsive Disorder
One-Sentence Summary
Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI) established for major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, and fibromyalgia. Among the 10 TxGNN-predicted indications for this drug, Obsessive-Compulsive Disorder is the only one backed by substantive real-world evidence, with 5 clinical trials (including one completed Phase 4 trial specifically titled “Duloxetine for the Treatment of Obsessive Compulsive Disorder”) and 20 publications, including one double-blind RCT.
Note on candidate selection: TxGNN’s top-ranked candidate by raw score, “benign paroxysmal torticollis of infancy,” and four personality-disorder candidates (ranks 4–7, all scoring an identical 0.9977636) have zero clinical trials or literature and are flagged in the evidence pack itself as likely knowledge-graph artifacts rather than genuine pharmacological hypotheses. This report focuses on rank 3, Obsessive-Compulsive Disorder, the only candidate with meaningful supporting evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not on file in this jurisdiction’s license registry (drug not marketed here); per literature in this evidence pack (PMID 31749717), duloxetine’s established indications are major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, and fibromyalgia |
| Predicted New Indication | Obsessive-Compulsive Disorder |
| TxGNN Prediction Score | 99.84% |
| Evidence Level | L2 |
| US Market Status | ✗ Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from the primary drug record (marked as a data gap). Based on information available in the literature evidence, duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI), a drug class whose efficacy in OCD has been explored as an alternative or adjunct to the standard first-line serotonergic agents (SSRIs, clomipramine).
Duloxetine’s approved psychiatric indications (major depressive disorder, generalized anxiety disorder) already share pathophysiological and neurotransmitter overlap with OCD, which is classified within the same serotonergic-dysregulation spectrum of anxiety-related disorders. Other SNRIs, notably venlafaxine, have documented anti-obsessional activity, and the literature evidence here explicitly frames duloxetine as a class-consistent alternative (PMID 16669725, 21779536).
The clinical evidence collected to date is concentrated in treatment-resistant OCD, where duloxetine is used as an augmentation agent alongside first-line therapy rather than as monotherapy — this is a materially narrower and lower-confidence claim than “first-line efficacy in OCD,” and should be represented as such in any downstream use of this prediction.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00464698 | Phase 4 | Completed | 20 | Directly titled “Duloxetine for the Treatment of Obsessive Compulsive Disorder”; assessed duloxetine efficacy in OCD (small sample) |
| NCT01404871 | N/A | Completed | 26 | Predicting medication response in OCD; participants unable to complete clomipramine/escitalopram arms could receive duloxetine under identical study procedures |
| NCT02476136 | N/A | Unknown | 8,800 | Individual patient data meta-analysis of antidepressant efficacy across anxiety disorders by initial severity; not duloxetine/OCD-specific but includes it |
| NCT05930912 | N/A | Unknown | 1 | Psychoanalytic treatment of ASD with psychiatric comorbidities including OCD; low relevance (N=1, unknown status) |
| NCT01944657 | N/A | Withdrawn | 0 | TMS vs. medication monotherapy for major depression; not executed, not OCD-specific |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 27811556 | 2016 | RCT | Journal of Clinical Psychopharmacology | Double-blind controlled trial evaluating duloxetine augmentation in treatment-resistant OCD |
| 28477500 | 2017 | Review/Meta-analysis | Journal of Affective Disorders | OCD shows a reduced placebo and antidepressant response compared to other anxiety disorders |
| 24766145 | 2014 | Review | Expert Opinion on Pharmacotherapy | Updated review of serotonergic antidepressants, including SNRIs, in OCD |
| 16669725 | 2006 | Review | The Journal of Clinical Psychiatry | Critical review of SNRIs (venlafaxine, and by class extension duloxetine) in OCD treatment |
| 31749717 | 2019 | Review | Frontiers in Psychiatry | Systematic review of duloxetine use beyond MDD/GAD, including OCD and other psychiatric conditions |
| 21779536 | 2011 | Review | Innovations in Clinical Neuroscience | Discusses SNRIs, including duloxetine, as pharmacological alternatives for OCD |
| 25637377 | 2015 | Open-label | International Journal of Neuropsychopharmacology | Open-label study of duloxetine specifically for OCD (DSM-IV) treatment |
| 39735048 | 2024 | Cohort/Case series | Cureus | Supratherapeutic duloxetine + CBT in severe treatment-resistant OCD with comorbid depression |
| 18208931 | 2008 | Case series | Journal of Psychopharmacology | Case series switching from SSRIs to duloxetine in resistant OCD |
| 17632660 | 2007 | Case report | Primary Care Companion to the Journal of Clinical Psychiatry | Case report of OCD responding to duloxetine |
US Market Information
No marketing authorization (NDA) is currently on file for this drug in this jurisdiction’s registry — market status is recorded as “Not Marketed” with 0 licenses. No approved-indication text is therefore available from local regulatory sources for this product.
Safety Considerations
Please refer to the package insert for safety information. No key warnings, contraindications, or drug-drug interaction records were retrieved for this drug in the current data cycle — this is logged as a blocking data gap (DG001), meaning the candidate cannot yet clear an initial safety review (S1) pending retrieval of official label data from the relevant regulatory source.
Conclusion and Next Steps
Decision: Hold
Rationale: Efficacy evidence for duloxetine in OCD is real but narrow — it supports use as an augmentation agent in treatment-resistant OCD (one completed Phase 4 trial, one double-blind RCT, and a decade-plus of consistent case series/reports), not first-line monotherapy. More critically, no safety label data (warnings, contraindications, drug interactions) could be retrieved in this cycle, and the drug has no current market license on file in this jurisdiction — both block progression past the initial safety review stage.
To proceed, the following is needed:
- Official package insert / label data (warnings, contraindications, DDI) — currently the blocking gap for S1 safety review
- Original approved indications and detailed mechanism of action from DrugBank or the regulatory source
- Larger controlled trials in OCD populations, since current RCT evidence is limited to small-sample, treatment-resistant/augmentation settings
- Route and dosage-form compatibility assessment once market/license data becomes available
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.